Trials have shown that rates of HIV infection are reduced if people not infected with HIV take anti-retrovirals - known as pre-exposure prophylaxis (PrEP). But adherence to a daily dose is a problem.
Academic rigor, journalistic flair
Articles on PrEPs
Displaying all articles
Three new studies conducted in South Africa provide insights into the engine that drives HIV transmission in the country.
Young women in southern Africa are most at risk of becoming infected with HIV. If they take a pre-exposure prophylaxis like Truvada it could change their lives.
Top contributors
-
Associate Professor and Director: Research at the Wits Reproductive Health and HIV Institute I, University of the Witwatersrand
-
Researcher and Programme Manager: Clinical Research Consortium for Wits Reproductive Health and HIV Institute (RHI), University of the Witwatersrand
-
Director, Centre for the AIDS Program of Research in South Africa (CAPRISA)
-
Professor of medicine and deputy director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine, University of Cape Town
